Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Dermatologic 1

Conditions

Mycosis Fungoides 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, B-Cell 1Leukemia, Myeloid, Acute 1Immunoblastic Lymphadenopathy 1Endometrial Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 28fludarabine phosphate 22Peripheral Blood Stem Cell Transplantation 22Whole-Body Irradiation 18Etoposide 17Mycophenolic Acid 14Doxorubicin 13Tacrolimus 12Vincristine 11Prednisone 11Cyclosporine 11Methotrexate 10Busulfan 10Melphalan 9Bortezomib 9Rituximab 8Antilymphocyte Serum 8Filgrastim 7Carboplatin 7Radiotherapy 6Lenalidomide 6Everolimus 6romidepsin 5Vorinostat 5Therapeutics 5etoposide phosphate 4Sirolimus 4Panobinostat 4Immunohistochemistry 4Ifosfamide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Immunoblastic Lymphadenopathy × sodium-iodide symporter × Clear all
NCT03017820 2026-05-28

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Mayo Clinic

Phase 1 Recruiting
99 enrolled
DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Immunoblastic Lymphadenopathy, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡